Navigation Links
Tanespimycin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...rporated (Nasdaq: KOSN ) today announced that the tanespimycin in Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for tanespimycin as a potential treatment for multiple myeloma is o...lment. TIME-1 is a pivotal Phase 3 trial comparing tanespimycin in combination with bortezomib (Velcade(R)) with b...
Tanespimycin in Medical Technology

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on th...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

...ster titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER...L. "The response data from this Phase 2 trial of tanespimycin plus trastuzumab have grown stronger as more patie...ve been treated, underscoring our observation that tanespimycin is a highly active and tolerable agent in patients...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...alating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(...n terms of convenience and ease of administration. tanespimycin is clearly an active and manageable agent and is d...ngful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma ac...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...rvival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous ...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... tanespimycin is Industry's First Hsp90 Inhibitor to Enter Regis...IME Registration Program Utilizes New, Proprietary tanespimycin Formulation HAYWARD...olling patients. This marks the opening of Kosan's tanespimycin in Myeloma Evaluation or "TIME" registration progr...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

... safety profile and Molecular of tanespimycin Therapeutics 13 (KOS-5: 953) -- ...lved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for mult...
Tanespimycin in Biological Technology

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...porting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cance...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velc...ultiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic ...

Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...alue for the company in the near-term. -- The tanespimycin TIME registration program in multiple myeloma, ...myeloma in early 2009. -- Kosan plans to advance tanespimycin in metastatic breast cancer. To lay the groun...Kosan plans to commence enabling studies with tanespimycin as monotherapy and as combination therapy beg...

Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook

... top priorities in 2008 are the advancement of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer clinical program, and the...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bort...
Other Tags
(Date:7/11/2014)... 11, 2014 Recently, Fadhits.com, the distinguished wedding ... kids prom dresses . To bring more benefits to ... also launched a special offer for these brand new items. ... , The company’s sales manager says gladly, “We are happy ... offer is to acknowledge all new and old customers and ...
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body Boot Camp, ... has held two charity workout events and is about to ... 7:15 - 8:30 at Col Summers City Park, SE 20th and ... raised $510 for Medical Teams International. Their second workout event resulted ... On July 26th, Johnson and Portland Fit Body Boot Camp ...
(Date:7/11/2014)... As reported by Forbes in the ... Genetics To Blame (6/30), Indino Downey has reportedly been ... to smoke it with. His father, well-known actor Robert ... inherited from him may have something to do with ... during the 1980s and 1990s for substance abuse before ...
(Date:7/11/2014)... Los Angeles dental implant expert ... and full mouth implants to replace missing teeth. Both ... dental implants from other tooth replacements: They replace the ... alone prevents the long-term complications of missing teeth, but ... comfort, appearance and systemic health. Mini implants broaden candidacy ...
Breaking Medicine News(10 mins):Health News:Promotion for Kids Prom Dresses Now Provided at Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
(Date:7/10/2014)... , July 1, 2014 Smart ... way for convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), ... GOOG ), Apple Inc. (NASDAQ: AAPL ... Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric ... to announce that the second series of 30 second spots ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
Other Contents